Clinical clinical JJ
practice practice NN
needs need VBZ
a a DT
common common JJ
parameter parameter NN
that that WDT
can can MD
provide provide VB
an a DT
early early JJ
reliable reliable JJ
estimation estimation NN
of of IN
the the DT
outcome outcome NN
of of IN
sublingual sublingual JJ
immunotherapy immunotherapy NN
-LRB- -lrb- -LRB-
SLIT slit NN
-RRB- -rrb- -RRB-
in in IN
an a DT
upcoming upcoming JJ
pollen pollen NN
season season NN
We we PRP
investigated investigate VBD
whether whether IN
the the DT
conjunctival conjunctival JJ
provocation provocation NN
test test NN
-LRB- -lrb- -LRB-
CPT cpt NN
-RRB- -rrb- -RRB-
can can MD
predict predict VB
the the DT
beneficial beneficial JJ
outcome outcome NN
of of IN
SLIT SLIT NNP
in in IN
patients patient NNS
with with IN
allergic allergic JJ
rhinoconjunctivitis rhinoconjunctivitis NN
after after IN
4 4 CD
weeks week NNS
of of IN
treatment.We treatment.we NN
conducted conduct VBN
two two CD
separate separate JJ
prospective prospective JJ
randomized randomize VBN
double-blind double-blind JJ
placebo-controlled placebo-controlled JJ
multicenter multicenter JJ
trials trial NNS
Adults adult NNS
18-75 18-75 CD
years year NNS
of of IN
age age NN
received receive VBD
placebo placebo NN
or or CC
SLIT SLIT NNP
tablets tablet NNS
containing contain VBG
tree tree NN
or or CC
grass grass NN
pollen pollen NN
allergoids allergoid NNS
and and CC
underwent undergo VBD
CPTs cpt NNS
Participants participant NNS
receiving receive VBG
SLIT SLIT NNP
were be VBD
divided divide VBN
into into IN
two two CD
groups group NNS
-LRB- -lrb- -LRB-
reactive reactive JJ
nonreactive nonreactive JJ
-RRB- -rrb- -RRB-
according accord VBG
to to TO
their they PRP$
CPT CPT NNP
reactions reaction NNS
after after IN
4 4 CD
weeks week NNS
of of IN
treatment treatment NN
These these DT
two two CD
groups group NNS
were be VBD
compared compare VBN
with with IN
regard regard NN
to to TO
clinical clinical JJ
outcome outcome NN
parameters parameter NNS
-LRB- -lrb- -LRB-
total total JJ
combined combined JJ
score score NN
rhinoconjunctivitis rhinoconjunctivitis NN
total total JJ
symptom symptom NN
score score NN
total total JJ
rescue rescue NN
medication medication NN
score score NN
well well RB
days day NNS
-RRB- -rrb- -RRB-
assessed assess VBN
during during IN
the the DT
pollen pollen NN
season season NN
for for IN
the the DT
14-day 14-day JJ
-LRB- -lrb- -LRB-
tree tree NN
-RRB- -rrb- -RRB-
or or CC
30-day 30-day JJ
-LRB- -lrb- -LRB-
tree/grass tree/grass NN
-RRB- -rrb- -RRB-
peaks peak VBZ
and and CC
for for IN
the the DT
entire entire JJ
60-day 60-day JJ
seasons season NNS
Participants participant NNS
global global JJ
evaluations evaluation NNS
of of IN
therapy therapy NN
after after IN
completing complete VBG
treatment treatment NN
were be VBD
also also RB
compared.The compared.the JJ
tree tree NN
pollen pollen NN
trial trial NN
randomized randomize VBD
188 188 CD
participants participant NNS
182 182 CD
participants participant NNS
were be VBD
evaluable evaluable JJ
76 76 CD
of of IN
whom whom WP
received receive VBD
SLIT SLIT NNP
and and CC
were be VBD
suitable suitable JJ
for for IN
this this DT
post post NN
hoc hoc FW
analysis analysis NN
The the DT
grass grass NN
pollen pollen NN
trial trial NN
included include VBD
90 90 CD
participants participant NNS
82 82 CD
participants participant NNS
were be VBD
evaluable evaluable JJ
44 44 CD
of of IN
whom whom WP
underwent undergo VBD
SLIT SLIT NNP
Comparing compare VBG
SLIT slit JJ
participants participant NNS
who who WP
reacted react VBD
to to TO
the the DT
CPT CPT NNP
after after IN
4 4 CD
weeks week NNS
-LRB- -lrb- -LRB-
tree tree NN
77.6 77.6 CD
grass grass NN
79.5 79.5 CD
-RRB- -rrb- -RRB-
with with IN
those those DT
who who WP
ceased cease VBD
to to TO
show show VB
a a DT
reaction reaction NN
-LRB- -lrb- -LRB-
tree tree NN
22.4 22.4 CD
grass grass NN
20.5 20.5 CD
-RRB- -rrb- -RRB-
-LRB- -lrb- -LRB-
tree tree NN
P p NN
0.0001 0.0001 CD
grass grass NN
P p NN
0.003 0.003 CD
-RRB- -rrb- -RRB-
the the DT
total total JJ
combined combined JJ
score score NN
for for IN
the the DT
14-day 14-day JJ
-LRB- -lrb- -LRB-
P p NN
0.017 0.017 CD
-RRB- -rrb- -RRB-
and and CC
30-day 30-day JJ
peaks peak NNS
-LRB- -lrb- -LRB-
P p NN
0.042 0.042 CD
-RRB- -rrb- -RRB-
as as RB
well well RB
as as IN
the the DT
rhinoconjunctivitis rhinoconjunctivitis NN
total total JJ
symptom symptom NN
score score NN
assessed assess VBN
for for IN
the the DT
14-day 14-day JJ
peak peak NN
-LRB- -lrb- -LRB-
P p NN
0.024 0.024 CD
-RRB- -rrb- -RRB-
were be VBD
significantly significantly RB
lower lower JJR
in in IN
the the DT
nonreactive nonreactive JJ
group group NN
of of IN
the the DT
tree tree NN
pollen pollen NN
trial trial NN
In in IN
the the DT
grass grass NN
pollen pollen NN
trial trial NN
the the DT
nonreactive nonreactive JJ
group group NN
rated rate VBD
their they PRP$
SLIT SLIT NNP
treatment treatment NN
significantly significantly RB
better better JJR
-LRB- -lrb- -LRB-
P p NN
0.019 0.019 CD
-RRB- -rrb- -RRB-
Using use VBG
clinically clinically RB
meaningful meaningful JJ
outcome outcome NN
parameters parameter NNS
during during IN
the the DT
pollen pollen NN
season season NN
both both CC
trials trial NNS
independently independently RB
led lead VBD
to to TO
similar similar JJ
results result NNS
when when WRB
comparing compare VBG
participants participant NNS
reactions reaction NNS
to to TO
the the DT
CPT CPT NNP
4 4 CD
weeks week NNS
after after IN
beginning begin VBG
SLIT SLIT NNP
These these DT
results result NNS
suggest suggest VBP
that that IN
CPT CPT NNP
allows allow VBZ
an a DT
early early JJ
estimation estimation NN
of of IN
allergic allergic JJ
rhinoconjunctivitis rhinoconjunctivitis NN
symptoms symptom NNS
before before IN
an a DT
upcoming upcoming JJ
season season NN
Thus thus RB
the the DT
CPT CPT NNP
can can MD
be be VB
used use VBN
as as IN
a a DT
valuable valuable JJ
parameter parameter NN
to to TO
predict predict VB
the the DT
beneficial beneficial JJ
outcome outcome NN
of of IN
ongoing ongoing JJ
SLIT.Both slit.both NN
trials trial NNS
registered register VBN
with with IN
the the DT
Medical Medical NNP
Ethics Ethics NNPS
Committee Committee NNP
of of IN
the the DT
North North NNP
Rhine Rhine NNP
Medical Medical NNP
Council Council NNP
-LRB- -lrb- -LRB-
EudraCT EudraCT NNP
numbers number NNS
2012-004916-79 2012-004916-79 CD
-LRB- -lrb- -LRB-
grass grass NN
pollen pollen NN
trial trial NN
-RRB- -rrb- -RRB-
and and CC
2013-002129-43 2013-002129-43 CD
-LRB- -lrb- -LRB-
tree tree NN
pollen pollen NN
trial trial NN
-RRB- -rrb- -RRB-
-RRB- -rrb- -RRB-
and and CC
the the DT
German german JJ
Federal Federal NNP
Ministry Ministry NNP
of of IN
Health Health NNP
-LRB- -lrb- -LRB-
Paul-Ehrlich-Institut Paul-Ehrlich-Institut NNP
-RRB- -rrb- -RRB-
